The Eliquis Paradox: US Price Caps Trigger Double-Digit Growth

 
• By Michael McCaughan
  
Eliquis growth is expected despite the price cuts from Medicare negotiations. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Pricing Debate

More from United States